“We are thrilled to have Dr. Duy join our program. He has made critical discoveries that inform how we can leverage epigenetic therapies to tackle hematologic malignancies,” said Johnathan Whetstine, PhD, the epigenetics program’s leader.
Before coming to Fox Chase, Duy was an instructor in cell and developmental biology at Weill Cornell Medicine Graduate School of Medical Sciences in New York City. He completed his postdoctoral studies at Weill Cornell Medicine, where he studied the epigenome and organoids. Duy recently received a grant from the Alternatives Research & Development Foundation to further develop these organoid models.
He carried out his doctoral studies in cancer biology and immunology at the University of Southern California and graduated summa cum laude from the University of Düsseldorf in Germany, where he received his MS degree. Duy’s thesis included the Philadelphia chromosome, which was discovered at Fox Chase in 1959.
Duy was awarded a postdoctoral fellowship by the Leukemia and Lymphoma Society. The William Guy Forbeck Research Foundation recently selected Duy as a Forbeck Scholar. This prestigious appointment recognizes early career cancer researchers for their achievements, research, and dedication to the field.